- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01334554
Study of Sildenafil Citrate on Insulin Resistance in African American
Effect of Sildenafil Citrate on Insulin Resistance and Endothelial Function in Obese African American Women
Obesity has a greater detrimental impact on the health of African American women than on any other racial or gender group. Nearly 80% of African American women are overweight or obese in the United States. Hypertension and insulin resistance are more prevalent among African American women as compared to men and Caucasians. These conditions put them at increased risk for the development of diabetes mellitus and cardiovascular disease.
Recent studies have reported that a substance named Nitric Oxide (NO)may have some beneficial effect on how the body handles blood sugar and blood pressure. Of interest,some studies have shown that African Americans have decreased function of NO in their blood vessels.
In this study proposal the investigators will test if increasing NO function with a PDE-5 inhibitor (sildenafil citrate) will improve pre-diabetes and the health of the inner layer of the blood vessels in obese African American women.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studieorter
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37232
- Vanderbilt University
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Race will be self-defined, but only subjects who report both parents of the same race will be included.
- Age 18-60 years old.
- The investigators will recruit subjects with wide range of BMI 30-45 kg/m2.
- Subjects who have metabolic syndrome or who have a fasting insulin >13. The diagnosis include 3 of the following:
Fasting blood glucose of greater than 100 Triglyceride levels of greater than 150 HDL cholesterol of less than 50 in women Blood pressure of at least 130/85, or on blood pressure medicine Waist girth of more than 35 inches in women. Subjects of childbearing potential will be required to have a negative serum/urine pregnancy test. In addition, they will be asked to use a reliable contraceptive method prior to enrollment as determined by the PI (Dr. Cyndya Shibao).
Exclusion Criteria:
- Previous allergic reactions to any of the study medication (sildenafil) or inability to take study medications as prescribed during the course of the study.
- Type 1 or 2 diabetes mellitus as defined by a fasting glucose of 126 mg/dl or greater.
- Use of antidiabetic medication (insulin, metformin, sulfonylurea, troglitazone)
- Cardiovascular disease such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis or hypertrophic cardiomyopathy.
- Current smokers.
- Significant weight change >5% from baseline in the past three months.
- Pregnancy or breast-feeding.
- History of serious neurological disease such as cerebral hemorrhage stroke, transient ischemic attack.
- History or presence of immunological or hematological disorders.
- Clinical significant gastrointestinal impairment that could interfere with drug absorption.
- Impaired hepatic function (aspartate amino transaminase [AST] and/or alanine amino transaminase [ALT] >1.5X upper limit of normal range).
- Impaired renal function (estimated glomerular filtration rate (eGFR) of <60mL/min).
- Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult.
- History of alcohol or drug abuse.
- Mental conditions rendering the subject unable to understand the nature, scope and possible consequences of the study.
- Inability to comply with the protocol, e.g. uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study.
- Patients must not be taking nitratest in any form (e.g., nitroglycerin, isosorbide dinitrate, nitroprusside, and others) during this study
- Patients on alpha-blocking drugs (doxazosin, terazosin , or prazosin) will be excluded
- Patients on protease inhibitors (ritonavir and others) will be excluded
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Placebo-jämförare: Placebo
placebo
|
No active drug
|
Experimentell: Sildenafil
Sildenafil 20 mg three times a day
|
20 mg three times a day.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Insulin Sensitivity
Tidsram: Insulin sensitivity measured at baseline and 4 weeks after the intervention
|
insulin sensitivity as measured by frequently sampled intravenous glucose tolerance test
|
Insulin sensitivity measured at baseline and 4 weeks after the intervention
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Endothelial Function
Tidsram: Difference between FMD at baseline and 4 weeks
|
Endothelial function was measured with flow mediated dilation, percent change
|
Difference between FMD at baseline and 4 weeks
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Cyndya Shibao, MD, Vanderbilt University
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 100713
- K23HL103976 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Fetma
-
SanionaAvslutadHypothalamic Injury-induced Obesity (HIO)Danmark
Kliniska prövningar på Sildenafil
-
University of PennsylvaniaWalter Reed National Military Medical CenterRekrytering
-
Rambam Health Care CampusOkänd
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI); PfizerAvslutad
-
Pfizer's Upjohn has merged with Mylan to form Viatris...AvslutadFarmakokinetiken för sildenafil oralt sönderfallande tablettformulering kontra Viagra® oral tablett.Erektil dysfunktionSingapore
-
The Cleveland ClinicAvslutadPulmonell hypertoni | Diffus parenkymal lungsjukdomFörenta staterna
-
iX Biopharma Ltd.Linear Clinical ResearchAvslutadErektil dysfunktionAustralien
-
Rigshospitalet, DenmarkGlostrup University Hospital, CopenhagenAvslutadBeckers muskeldystrofiDanmark
-
N4 Pharma UK Ltd.BDD Pharma LtdAvslutadErektil dysfunktionStorbritannien
-
University Hospital, GrenobleAvslutad
-
University Hospital, MontpellierIndragenPulmonell hypertoni | Enkelkammar | Univentrikulärt hjärta